- Current report filing (8-K)
June 03 2009 - 4:06PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
Current Report Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
June 2, 2009
AMYLIN PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
Delaware
(State or Other
Jurisdiction of
Incorporation)
|
|
0-19700
(Commission File
Number)
|
|
33-0266089
(I.R.S. Employer
Identification No.)
|
9360 Towne Centre Drive
San Diego, California 92121
(Address of principal executive offices and zip code)
Registrants telephone number, including area
code:
(858)
552-2200
Check the appropriate box below if the Form 8-K is
intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions (
see
General
Instruction A.2. below):
o
Written communications
pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o
Soliciting material pursuant
to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act
(17 CFR 240.14d-2(b))
o
Pre-commencement communications pursuant to Rule 13e-4(c) under
the Exchange Act (17 CRF 240.13e-4(c))
Item
8.01 Other Events.
On
June 2, 2009, Amylin Pharmaceuticals, Inc. issued a press release
announcing that the independent Inspector of Elections for the Companys 2009
Annual Meeting of Stockholders has completed its preliminary tabulation of
shareholder votes. The preliminary
tabulation indicates that Amylins stockholders voted to elect ten of Amylins
Director nominees to the companys Board of Directors and two candidates
nominated by two Amylin stockholders.
The press release also provided preliminary results of proposals that
were voted upon at the meeting, including the rejection of Carl Icahns
proposal to change Amylins jurisdiction of incorporation from Delaware to
North Dakota. A final tally of the
voting results on Director elections and all proposals voted upon at the
meeting will be published in Amylins next quarterly report on Form 10-Q
which will be filed with the Securities and Exchange Commission.
A copy of the press release is attached as Exhibit 99.1 and is
incorporated herein by reference.
Item
9.01. Financial Statements and Exhibits.
(d)
|
Exhibits.
|
|
|
|
|
|
|
|
Number
|
|
Description
|
|
|
|
|
|
99.1
|
|
Press release issued by
Amylin on June 2, 2009.
|
2
SIGNATURES
Pursuant to the
requirements of the Securities Exchange Act of 1934, as amended, the registrant
has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.
|
AMYLIN PHARMACEUTICALS, INC.
|
|
|
|
|
|
Dated: June 3,
2009
|
By:
|
/s/ Lloyd A. Rowland
|
|
|
Lloyd A. Rowland
|
|
|
Vice President, Governance and
Compliance, and Secretary
|
3
EXHIBIT
INDEX
Number
|
|
Description
|
|
|
|
99.1
|
|
Press release issued by
Amylin on June 2, 2009.
|
4
Amylin Pharmaceuticals, Inc. (MM) (NASDAQ:AMLN)
Historical Stock Chart
From Jun 2024 to Jul 2024
Amylin Pharmaceuticals, Inc. (MM) (NASDAQ:AMLN)
Historical Stock Chart
From Jul 2023 to Jul 2024